10-Q: Nika Pharma Q2 2025: Cash Up, Losses Down, Control Issues

Nika Pharmaceuticals, Inc. reported reduced net losses and increased cash for Q2 2025, but faces going concern doubts and internal control deficiencies.

Summary

• Net loss for the three months ended June 30, 2025, decreased to $18,381 from $22,457 in the prior year period.
• Net loss for the six months ended June 30, 2025, decreased to $31,327 from $65,342 in the prior year period.
• Cash balance increased to $15,616 as of June 30, 2025, from $2,083 as of December 31, 2024.
• Operating expenses for the three months ended June 30, 2025, decreased to $18,381 from $22,457 in the prior year period, primarily due to a significant reduction in professional fees.
• The company has an accumulated deficit of $8,958,938 as of June 30, 2025, and has generated no revenue to date.
• Disclosure controls and procedures were deemed not effective due to a lack of an audit committee and separation of duties.
• The company continues to rely on loans from related parties, with $45,000 received in the six months ended June 30, 2025.

Sentiment

Score: 3

Explanation: The company shows some positive trends in reducing net loss and increasing cash, but these are overshadowed by the persistent lack of revenue, increasing accumulated deficit, significant going concern warning, and critical internal control deficiencies. The cancellation of a key acquisition also adds uncertainty. Overall sentiment is negative due to fundamental operational and governance issues.

Positives

• Reduced net loss for both the three and six months ended June 30, 2025, compared to the prior year periods.
• Significant increase in cash balance to $15,616 as of June 30, 2025.
• Decreased professional fees contributed to lower overall operating expenses.
• Reduced net cash used in operating activities for the six months ended June 30, 2025.
• Successful uplisting to OTCQB in December 2024.
• Acquisition of exclusive rights for several pharmaceutical products and dietary supplements, and four new technologies for generic drugs and a dietary supplement.
• Progress towards establishing a pharmaceutical factory in Bulgaria, including a supply agreement for a vial production line.

Negatives

• No revenue generated to date, indicating a lack of operational income.
• Accumulated deficit of $8,958,938 as of June 30, 2025, and increasing total stockholders' deficit.
• Substantial doubt about the company's ability to continue as a going concern.
• Reliance on related party loans for financing operations.
• Disclosure controls and procedures were deemed not effective due to a lack of an audit committee and separation of duties.
• Cancellation of the acquisition of Nika Pharmaceuticals, Ltd. and the beneficial ownership of a factory building and land, which was previously highlighted as a significant asset.
• Changes in accounting firms due to resignation and lack of necessary expertise, which could indicate instability or complexity in financial reporting.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to accumulated deficit and no revenue.
• Inability to raise additional capital through equity, debt, or a merger, which is necessary to fund operations and business plans.
• Reliance on related party financing, which may not be sustainable or sufficient.
• Ineffective disclosure controls and procedures due to lack of an audit committee and separation of duties, posing risks to financial reporting reliability.
• Uncertainty regarding the completion and operationalization of the pharmaceutical factory in Bulgaria.
• Risks associated with the development, production, and distribution of pharmaceutical products and dietary supplements, including regulatory approvals and market acceptance.
• Potential for actual results to differ materially from forward-looking statements due to changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, and competition.

Future Outlook

The company aims to continue its business plan, potentially raising additional capital through equity, debt, or seeking a merger target. It expects to receive an estimated profit of around $1,120 per set for ITV-1 once the pharmaceutical factory is completed and Nika Europe, Ltd. begins production. The vial production line equipment is scheduled to be produced, delivered, and installed in the Bulgarian production building by the end of Q4 2024.

Management Comments

• "We believe we are not exposed to any significant credit risk on cash."
• "The Company is glad that it has found a competent accounting firm that has the necessary expertise in both US GAAP and IFRS, which will allow it to cater to the Company's international accounting needs."
• "Our Chief Executive Officer and Chief Financial Officer evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on that evaluation, they concluded that our disclosure controls and procedures were not effective for the quarterly period ended June 30, 2025."
• "The Company cannot be certain that it will be successful in this strategy [of finding a merger target]."

Industry Context

Nika Pharmaceuticals operates in the pharmaceutical and dietary supplement sectors, focusing on acquiring exclusive rights to various compounds and technologies, including a potential HIV treatment (TNG), and developing manufacturing capabilities in Europe. The industry is highly regulated, capital-intensive, and competitive, requiring significant investment in R&D, clinical trials, and production facilities. The company's strategy of acquiring existing rights and technologies, alongside building a factory, suggests a focus on product commercialization and manufacturing rather than early-stage drug discovery. The reliance on related party financing and the "going concern" warning are common challenges for early-stage or developing pharmaceutical companies that have not yet achieved revenue generation.

Comparison to Industry Standards

• The company's lack of revenue and significant accumulated deficit are not uncommon for early-stage pharmaceutical companies, but the "going concern" warning indicates a critical financial vulnerability.
• The reliance on related party loans for operational funding is a common characteristic of small, pre-revenue companies, but it raises questions about long-term financial independence compared to established pharmaceutical firms that access broader capital markets.
• The acquisition of exclusive rights to compounds like TNG (Thymus Nuclear Glycoprotein), which completed Phase III clinical trials in 1998, suggests a focus on potentially re-commercializing or further developing older, established research, rather than novel drug discovery typical of major pharmaceutical innovators.
• The plan to build a pharmaceutical factory in Bulgaria and acquire vial production line equipment aligns with industry trends of vertical integration and establishing regional manufacturing hubs, similar to how larger players like Pfizer or Novartis maintain global production networks, albeit on a much smaller scale for Nika.
• The reported ineffective disclosure controls due to a lack of an audit committee and separation of duties fall below standard corporate governance practices expected of publicly traded companies, regardless of size, and are a significant red flag compared to industry leaders.

Management Changes

Corporate Governance

Legal Proceedings

• There are no legal proceedings against the Company and the Company is unaware of any proceedings contemplated against it.

Related Party Transactions

• Nika Europe, Ltd. advanced $45,000 to the Company for general operating expenses; the total amount due to Nika Europe is $45,000 as of June 30, 2025. This advance is non-interest bearing and due on demand.
• Dimitar Slavchev Savov, CEO, advanced funds to the Company for general operating expenses; the total amount due to Mr. Savov is $205,164 as of June 30, 2025. This advance is non-interest bearing and due on demand.
• Nika Pharmaceuticals LTD advanced $34,000 to the Company for general operating expenses; the total amount due to Nika Pharmaceuticals LTD is $34,000 as of June 30, 2025. This advance is non-interest bearing and due on demand.
• The Company issued 8,000,000 shares of Preferred stock to Dimitar Slavchev Savov for exclusive rights to Thymus Nuclear Glycoprotein (TNG) from VITAL FE Joint Stock Company, where Mr. Savov is a 70% owner.
• The Company issued 2,000,000 shares of Preferred stock to Dimitar Slavchev Savov for exclusive rights to Carotilen and Physiolong from MICAR 11 LTD., which is wholly owned by Mr. Savov.
• The Company signed an Exclusive Rights Agreement with Dimitar Slavchev Savov for 6 additional dietary supplements.
• The Company signed a Joint Business Agreement with Immunotech Laboratories BG, Ltd., where Dimitar Slavchev Savov owns 51%.
• Dimitar Slavchev Savov paid 75,000 BGN (approximately $42,491 USD) for four technologies acquired by Nika Europe Ltd. from AIPFPCB.
• Dimitar Slavchev Savov paid an initial down payment of $191,534 for the vial production line equipment for Nika Europe, Ltd.
• Nika Pharmaceuticals, Ltd. (wholly owned and managed by Dimitar Savov at the time) made a non-monetary in-kind contribution of a production building and land valued at approximately $2,045,209 USD to Nika Europe, Ltd. (this acquisition was later cancelled).
• The acquisition of Nika Pharmaceuticals, Ltd. (which was owned by Dimitar Slavchev Savov) was cancelled, and ownership was returned to him.

Stakeholder Impact

• Shareholders face significant risk due to the "going concern" warning, accumulated deficit, and reliance on related party financing. Potential for dilution if future capital raises involve equity. The cancellation of the Nika Pharmaceuticals, Ltd. acquisition removes a significant asset from the company's practical ownership, which could negatively impact asset value.
• Creditors (Related Parties) are providing ongoing financing, indicating their continued support but also their exposure to the company's financial health.
• The company's ability to continue as a going concern directly impacts job security for employees.
• Future customers and partners for pharmaceutical products and dietary supplements may face uncertainty regarding product availability and company stability given the financial and operational challenges.

Next Steps

• Raise additional capital through equity, debt, or borrowings from financial institutions.
• Seek a merger target in the form of an operating entity if the current business plan cannot be fulfilled.
• Complete the pharmaceutical factory in Bulgaria.
• Produce, deliver, and install the vial production line equipment by the end of Q4 2024.
• Nika Europe, Ltd. to organize and bear the costs of production for ITV-1.

Key Dates

Recommendation

Despite a reduction in net loss and an increase in cash, the company has no revenue, a growing accumulated deficit, and a stated "substantial doubt about its ability to continue as a going concern." Critical internal control deficiencies (lack of audit committee, separation of duties) indicate severe governance issues. The cancellation of a significant asset acquisition (factory building and land) further undermines its asset base and strategic direction. The reliance on related party financing is unsustainable for long-term growth. These fundamental issues present extreme risk, making the stock a strong sell for any seasoned investor.

Keywords

Pharmaceuticals, Biotechnology, SEC Filing, 10-Q, Financial Report, OTC Markets, Drug Development, Dietary Supplements, Corporate Governance, Going Concern, Bulgaria, Manufacturing, Clinical Trials, HIV Treatment